Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2016

View Archived Issues

Gilead opens phase II/III study of fixed-dose combination in young patients with HIV-1 infection

New phase Ib study investigates dantrolene sodium for Wolfram syndrome

Primex Pharmaceuticals submits MAA for ADV-6209

Synthetic Biologics awarded CDC contract for SYN-004

RedHill Biopharma provides update on phase III study of RHB-104

Asceneuron receives grant from MJFF

ICU Medical to acquire Pfizer's Hospira Infusion Systems business

Vaccinex, Merck KGaA form collaboration to evaluate VX15/2503 plus avelumab in NSCLC

Santen, RIKEN and FBRI to develop novel retinal disease treatments

Engility awarded task order by Walter Reed for Chikungunya virus vaccine work

FDA accepts Coherus' BLA submission for pegfilgrastim biosimilar

ZF-AAV constructs enables long-term mutant Huntingtin repression in mice

Promising phase II data presented for E-52862

First patient enrolled in Reata Pharmaceuticals' phase III study of bardoxolone methyl

Boston Therapeutics and Advance Pharmaceutical report topline data from study of BTI-320

University of Ljubljana patents PSMB8 inhibitors

NIH grant supports work at IDRI to develop RNA-based Zika virus vaccine

Akarna Therapeutics discloses FXR agonists

Shanghai Yingli Pharmaceutical describes URAT1 inhibitors

Mironid develops PDE4 activators

Hokkaido University presents oxidative stress-induced cell death inhibitors

AstraZeneca to divest ex-U.S. Rhinocort Aqua rights to Cilag

MonoSol Rx and Lupin to develop pediatric products utilizing PharmFilm technology

EMA grants orphan drug designation to Videregen's replacement trachea product

TRPM8 antagonist attenuates oxaliplatin-induced cold allodynia in vivo

GSK makes success payment to Cancer Research Technology and University of Manchester

Teva to commercialize two Celltrion biosimilar candidates in U.S. and Canada

NIH awards support research on the peripheral nervous system

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...